Paclitaxel plus cisplatin as adjuvant chemotherapy for advanced cervical cancer
Phase 2
Recruiting
- Conditions
- terine cervical cancer
- Registration Number
- JPRN-jRCTs051180220
- Lead Sponsor
- Sumi Toshiyuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 125
Inclusion Criteria
(1) Uterine cervical cancer confirmed by histology
(2) Pathological findings
More than half cervical stromal invasion and positive lymphovascular space invasion
Exclusion Criteria
(1) Active infection
(2) Severe complication
(3) Multiple primary cancers with disease-free period less than 5 years, except carcinoma in situ or intra mucosal disease curedby local therapy
(4) Interstitial pneumonia, pulmonary fibrosis
(5) Massive ascites, massive pleural infusion
(6) Allergy to paclitaxel or cisplatin
(7) Severe allergy to medicine
(8) The patient who is not safe to include in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method